Enlivex Receives Regulatory Authorization For The Initiation Of A Placebo-Controlled Phase I/II Trial Evaluating Allocetra In Up To 46 Patients With Thumb Osteoarthritis
Portfolio Pulse from Benzinga Newsdesk
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) has received regulatory authorization from the Israeli Ministry of Health to initiate a Phase I/II trial for Allocetra™ in treating thumb osteoarthritis. This is the first study of Allocetra™ in thumb osteoarthritis, a condition with no FDA-approved therapy, and follows ongoing trials in knee osteoarthritis.
June 03, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enlivex Therapeutics Ltd. has received regulatory approval to start a Phase I/II trial for Allocetra™ in thumb osteoarthritis. This marks the first study of Allocetra™ in this condition, which currently has no FDA-approved treatments.
The regulatory approval for a new clinical trial is a significant milestone for Enlivex Therapeutics. It opens up potential new markets and demonstrates progress in their research and development efforts. This news is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100